Dr Gerard Francisco (TIRR Memorial Hermann Hospital, USA) focused on real-world onabotulinum toxin A treatment utilisation. He evaluated efficacy across multiple aetiologies of spasticity from the Adult Spasticity International Registry (ASPIRE) study. Dr Francisco examined data - derived from the international, multicentre, prospective, observational registry - from adult patients with spasticity either due to stroke (56%), multiple sclerosis, cerebral palsy, traumatic brain injury, spinal cord injury, or other illnesses, treated with onabotulinum toxin A. In total, 730 participants, of whom 37% were previously treatment-naïve to botulinum toxins, received at least one onabotulinum toxin A treatment. Total dosages per treatment session ranged from 45 to 1,038 units. The most common symptoms prompting treatments were equinovarus foot and clenched fist (in stroke). Most physicians and patients reported being "satisfied" or "extremely satisfied" with treatment that helped manage sp...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Predictors of response Next Article
Daxibotulinum toxin in isolated cervical dystonia »
Table of Contents: TOXINS 2019
New Versions of Botulinum Toxins
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.